Dr. Sasaki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2016 - 2017
- Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2010 - 2013
- Tokyo Medical and Dental UniversityClass of 2006
Certifications & Licensure
- TX State Medical License 2014 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial Start of enrollment: 2005 Jun 08
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 46 citationsHigh-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic signific...Hui Yang, Guillermo Garcia-Manero, Koji Sasaki, Guillermo Montalban-Bravo, Zhenya Tang
Leukemia. 2022-09-01 - 45 citationsPhase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.Koji Sasaki, Jason Gotlib, Ruben A. Mesa, Kate J. Newberry, Farhad Ravandi
Leukemia & Lymphoma. 2015-02-02 - 81 citationsOutcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimensAbhishek Maiti, Caitlin R. Rausch, Jorge E. Cortes, Naveen Pemmaraju, Naval Daver
Haematologica. 2020-06-04
Abstracts/Posters
- Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and TherapyKoji Sasaki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic SyndromesKoji Sasaki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)Koji Sasaki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
- Can Dasatinib Dose Be Halved in Low-Risk CML?December 14th, 2021
- Current Status and Novel Strategy of CMLMarch 29th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: